G1 Therapeutics Net Income 2016-2021 | GTHX

G1 Therapeutics net income from 2016 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
G1 Therapeutics Annual Net Income
(Millions of US $)
2020 $-99
2019 $-122
2018 $-85
2017 $-65
2016 $-35
2015 $-22
G1 Therapeutics Quarterly Net Income
(Millions of US $)
2021-06-30 $-39
2021-03-31 $-26
2020-12-31 $-25
2020-09-30 $-12
2020-06-30 $-31
2020-03-31 $-31
2019-12-31 $-35
2019-09-30 $-32
2019-06-30 $-31
2019-03-31 $-24
2018-12-31 $-24
2018-09-30 $-20
2018-06-30 $-21
2018-03-31 $-20
2017-12-31 $-17
2017-09-30 $-16
2017-06-30 $-15
2017-03-31 $-17
2016-12-31
2016-09-30 $-8
2016-06-30 $-8
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.581B $0.045B
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company's product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.038B 8.59
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.127B 20.54
Biohaven Pharmaceutical Holding (BHVN) United States $8.605B 0.00
Emergent Biosolutions (EBS) United States $2.673B 6.45
Arcus Biosciences (RCUS) United States $2.441B 0.00
Myovant Sciences (MYOV) United Kingdom $1.860B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.754B 0.00
Zymeworks (ZYME) Canada $1.075B 0.00
Ambrx Biopharma (AMAM) United States $0.524B 0.00
SQZ Biotechnologies (SQZ) United States $0.335B 0.00
Enzo Biochem (ENZ) United States $0.158B 15.48